EP1071465A1 - Amorphe gläser zur stabilisierung von empfindlichen produkten - Google Patents
Amorphe gläser zur stabilisierung von empfindlichen produktenInfo
- Publication number
- EP1071465A1 EP1071465A1 EP99910516A EP99910516A EP1071465A1 EP 1071465 A1 EP1071465 A1 EP 1071465A1 EP 99910516 A EP99910516 A EP 99910516A EP 99910516 A EP99910516 A EP 99910516A EP 1071465 A1 EP1071465 A1 EP 1071465A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- mannitol
- drying
- glass
- compound
- inositol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
- A23L29/37—Sugar alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Definitions
- a common reactivity of sugar glasses is the reducing action of the carbonyl group and the degradation products formed are often the familiar carbonyl-amine compounds of the Maillard reaction (Ellis G.P. The Maillard reaction. Adv. Carbohyd. Chem. 14 63-134 (1959)). Because the Maillard reaction is temperature dependent, it is only slowly progressive at low temperatures. Many glass-forming materials give excellent preservation of activity during the drying process itself but the product subsequently undergoes progressive deterioration unless stored under refrigeration.
- trehalose Because it is subsequently degraded in the body by the specific enzyme, trehalase, to two molecules of glucose, trehalose possesses many of the properties of the ideal industrial stabiliser for foods and medical products.
- a large scientific and patent literature has now developed on trehalose stabilisation of foods, vaccines, diagnostics and drugs.
- the disadvantages of trehalose are that it is as yet not approved by the regulatory authorities, it is expensive and it contains contaminating reducing sugars, especially glucose, in all but the most rigorously purified material.
- the effect of these substances is dose dependent and below a threshold concentration they do not work.
- the substances useful in accordance with this invention promote the drying of mannitol solutions as glasses rather than crystals.
- One of the most potent materials is the borate ion either as boric acid, or tetraborate salts of sodium or potassium. This probably forms a network complex with mannitol or even a covalent compound, sodium mannitoborate.
- the quality of the glasses made by this process is high.
- the glass transition temperature (Tg) of 1 :1 w/w mannitol/calcium lactate glass is around 68°C ( Figure 1). This compares with a Tg of around 90°C for a trehalose/sodium sulphate glass dried under the same conditions ( Figure 2). Both types of glass have Tg's well above any possible ambient storage temperature and, because the glasses are chemically inert and non-reactive, the entrapped products are stable at room temperatures and require no refrigeration of any kind.
- Figure 1 shows differential scanning calorimetry of a 50 / 50 w/w mannitol / calcium lactate glass showing a clear glass transition at a temperature of 68 °C;
- Figure 2 shows differential scanning calorimetry of a 50 / 50 w/w trehalose / calcium lactate glass showing a clear glass transition at a temperature of 90 °C;
- Figure 3 shows the percentage recovery of alkaline phosphatase activity after vacuum- drying in either trehalose or formula 7 containing mannitol, inositol, galactitol and degraded gelatin (Byco C) followed by storage at 37°C or 50°C for up to 6 weeks. There is no loss with formula 7 but serious losses with trehalose;
- Figure 4 shows the percentage recovery of alkaline phosphatase activity after freeze-drying in either trehalose or formula 7 containing mannitol, inositol, galactitol and degraded gelatin (Byco C) followed by storage at 37°C or 50°C for up to 7 weeks. There is little loss with either stabiliser;
- Figure 5 shows the percentage recovery of Erythropoietin (EPO) after vacuum-drying in either trehalose or formula 8 containing mannitol, inositol, galactitol and calcium lactate followed by storage at 37°C or 50°C for up to 6 weeks. While there is serious losses with trehalose, no loss occurs with formula 8; and
- Figure 6 shows the percentage recovery of EPO after freeze-drying in either trehalose or formula 7 containing mannitol, Inositol, galactitol and degraded gelatin (Byco C) or formula 8 in which calcium lactate was substituted for the gelatin. After storage at 37°C or 50°C for 7 weeks, there is no loss with any of the stabilising formulations.
- Figure 7 shows the percentage recovery of alkaline phosphatase activity after spray drying formula 9 to which had been added insoluble calcium phosphate powder to increase the density of the glass microspheres. After storage at either 37°C or 55°C for up to 90 days there was no significant loss of activity.
- Figure 8 shows the percentage recovery alkaline phosphatase activity after spray drying formula 1 1 to which had been added insoluble barium sulphate powder to increase the density of the glass microspheres. After storage at either 37"C or 55°C for up to 90 days there was again no significant loss of activity.
- a network forming additive such as sodium or potassium tetraborate
- a network forming additive such as sodium or potassium tetraborate
- Affinity purified alkaline phosphatase from bovme intestinal mucosa (Sigma Chemical Co cat No p-8647) was vacuum-d ⁇ ed or freeze-d ⁇ ed m 200 ⁇ l volumes in formulation Number 7 above or in trehalose.
- Vacuum drying was done at a shelf temperature of 40°C and a vacuum of 30- 100 milhtorr for 4 hr The temperature was then ramped gradually to 60°C over 1 hr and the vials were stoppered and removed from the vacuum chamber for high temperature storage trials Freeze-drying was done in a Labconco dryer at an initial shelf temperature of-40°C for 3 hr at a vacuum of 30-100 milhtorr The shelf temperature was then ramped to 0°C at 5°C / mm and held for 1 hr The shelf temperature was then raised to 40°C at 5°C / min and secondary drying was continued for a further 3 hr when the vials were stoppered under vacuum and removed for storage trials
- EPO was vacuum dried or freeze-d ⁇ ed as above in the same solutions and also in a va ⁇ ant of formulation 7 in which calcium lactate was substituted for Byco C (Formula 8), and then subjected to the same stability tests before being assayed by a standard 2-s ⁇ te sandwich Enzyme Immunoassay
- the fluorescent protein R-Phycoeryth ⁇ n was air-dried in trehalose, formula 3 or formula 4 on a hotplate as described in Example 1
- the intensity of fluorescence was gauged visually when illuminated with a UV lamp.
- the material dried in formula 3 was masked by an intense silver autofluorescence from the Byco C while the material dried in formula 4 fluoresced with the characteristic orange colour with apparently undimmished intensity
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9805699.7A GB9805699D0 (en) | 1998-03-18 | 1998-03-18 | New stabilising glasses |
GB9805699 | 1998-03-18 | ||
GB9820689 | 1998-09-23 | ||
GBGB9820689.9A GB9820689D0 (en) | 1998-09-23 | 1998-09-23 | New stabilising glasses |
PCT/GB1999/000820 WO1999047174A1 (en) | 1998-03-18 | 1999-03-17 | Amorphous glasses for stabilising sensitive products |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1071465A1 true EP1071465A1 (de) | 2001-01-31 |
Family
ID=26313295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99910516A Withdrawn EP1071465A1 (de) | 1998-03-18 | 1999-03-17 | Amorphe gläser zur stabilisierung von empfindlichen produkten |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1071465A1 (de) |
AU (1) | AU2945199A (de) |
WO (1) | WO1999047174A1 (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6190701B1 (en) | 1999-03-17 | 2001-02-20 | Peter M. Ronai | Composition and method for stable injectable liquids |
GB2362555A (en) * | 2000-05-26 | 2001-11-28 | British Sugar Plc | Amorphous sugar coatings |
US6653062B1 (en) | 2000-07-26 | 2003-11-25 | Wisconsin Alumni Research Foundation | Preservation and storage medium for biological materials |
DK1452171T3 (da) * | 2000-10-13 | 2010-04-06 | Nova Bio Pharma Technologies Ltd | Farmaceutiske væskesuspensioner |
US6623762B2 (en) | 2001-02-16 | 2003-09-23 | Cambridge Biostability Ltd. | Composition and method for controlled release injections |
GB0406013D0 (en) | 2004-03-17 | 2004-04-21 | Chiron Srl | Analysis of saccharide vaccines without interference |
GB0523638D0 (en) * | 2005-11-21 | 2005-12-28 | Cambridge Biostability Ltd | Pharmaceutical device for the administration of substances to patients |
GB0918450D0 (en) | 2009-10-21 | 2009-12-09 | Innovata Ltd | Composition |
CN107340387B (zh) * | 2017-06-20 | 2019-02-01 | 广东云天抗体生物科技有限公司 | 一种细胞因子elisa标准品的制备方法 |
IT201900025063A1 (it) * | 2019-12-20 | 2021-06-20 | Idi Integratori Dietetici Italiani S R L | Composizioni gastroresistenti comprendi inositolo e/o estratto di gymnema sylvestre, loro composizioni farmaceutiche e nutraceutiche e loro uso |
CN112538111B (zh) * | 2020-12-09 | 2022-04-29 | 深圳市亚辉龙生物科技股份有限公司 | 新冠病毒单链抗体及质控品和制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6197229A (ja) * | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | 安定なエリトロポエチン製剤 |
US5621094A (en) * | 1990-05-14 | 1997-04-15 | Quadrant Holdings Cambridge Limited | Method of preserving agarose gel structure during dehydration by adding a non-reducing glycoside of a straight-chain sugar alcohol |
ATE197550T1 (de) * | 1993-02-23 | 2000-12-15 | Genentech Inc | Stabilisierung von mit organischen lösungsmittel behandelten polypeptiden mit einem hilfsstoff |
US5955448A (en) * | 1994-08-19 | 1999-09-21 | Quadrant Holdings Cambridge Limited | Method for stabilization of biological substances during drying and subsequent storage and compositions thereof |
FR2719479B1 (fr) * | 1994-05-04 | 1996-07-26 | Sanofi Elf | Formulation stable lyophilisée comprenant une protéine: kit de dosage. |
EP0831790B1 (de) * | 1995-06-07 | 2003-05-07 | Elan Drug Delivery Limited | Verfahren zur stabilen einarbeitung von substanzen in trockene geschäumte glasmatrizen und auf diese weise hergestellte zusammensetzungen |
GB9705588D0 (en) * | 1997-03-18 | 1997-05-07 | Anglia Research Foundation | Stable particle in liquid formulations |
-
1999
- 1999-03-17 EP EP99910516A patent/EP1071465A1/de not_active Withdrawn
- 1999-03-17 WO PCT/GB1999/000820 patent/WO1999047174A1/en not_active Application Discontinuation
- 1999-03-17 AU AU29451/99A patent/AU2945199A/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO9947174A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU2945199A (en) | 1999-10-11 |
WO1999047174A1 (en) | 1999-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100777349B1 (ko) | 민감한 생물학적 물질의 보존방법 | |
Izutsu et al. | Increased stabilizing effects of amphiphilic excipients on freeze-drying of lactate dehydrogenase (LDH) by dispersion into sugar matrices | |
Izutsu et al. | Decreased protein-stabilizing effects of cryoprotectants due to crystallization | |
EP1071465A1 (de) | Amorphe gläser zur stabilisierung von empfindlichen produkten | |
US6669963B1 (en) | Stable particle in liquid formulations | |
RU2191003C2 (ru) | Композиция и способ стабилизации биологических материалов путем сушки без замораживания | |
EP0541556B1 (de) | Verfahren zur stabilisierung von biologischen macromolekularen substanzen und anderen organischen produkten | |
US6071428A (en) | Stable compositions | |
US6313102B1 (en) | Method for stabilization of biological substances during drying and subsequent storage and compositions thereof | |
US7153472B1 (en) | Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers | |
JPH0853361A (ja) | 安定なタンパク含有凍結乾燥製剤およびアッセイキット | |
EP2633860B1 (de) | Stabilisierte Faktor-IX-Formulierungen mit Trehalose | |
Iglesias et al. | Adsorption isotherm of amorphous trehalose | |
Jangle et al. | Vacuum foam drying: an alternative to lyophilization for biomolecule preservation | |
EP0415567A2 (de) | Mittel und Verfahren zur Stabilisierung organischer Verbindungen | |
Pisal et al. | Vacuum foam drying for preservation of LaSota virus: effect of additives | |
US20230144557A1 (en) | Method of long-term preservation of chemical and biological species using sugar glasses | |
AU4065393A (en) | Pharmaceutical compositions containing IL-6 | |
AU760940B2 (en) | Water soluble dry compositions | |
CN101991857B (zh) | 稳定型药物制剂及其制备方法 | |
EP1254944B1 (de) | Hydrophobe aminosäuren enthaltende trockene zusammensetzung | |
EP0169700B1 (de) | Pharmazeutische Zusammensetzungen von Ceftazidim | |
Hajare et al. | Foam dried composite glass: An alternative to lyophilization for stability enhancement of bendamustine hydrochloride | |
Hajare Ashok et al. | Foam Dried Composite Glass: An alternative to Lyophilization for Stability Enhancement of Bendamustine Hydrochloride | |
KR100857889B1 (ko) | 건조 라이게이즈 조성물 및 이의 제조 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
17P | Request for examination filed |
Effective date: 20001011 |
|
17Q | First examination report despatched |
Effective date: 20031201 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20040414 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1034667 Country of ref document: HK |